Advertisement
UK markets close in 40 minutes

  • FTSE 100

    8,116.37
    -50.39 (-0.62%)
     

  • FTSE 250

    20,209.99
    -12.09 (-0.06%)
     

  • AIM

    764.64
    -0.54 (-0.07%)
     

  • GBP/EUR

    1.1805
    +0.0031 (+0.26%)
     

  • GBP/USD

    1.2675
    +0.0025 (+0.20%)
     

  • Bitcoin GBP

    48,823.34
    -681.54 (-1.38%)
     

  • CMC Crypto 200

    1,332.44
    -12.07 (-0.90%)
     

  • S&P 500

    5,476.57
    +1.48 (+0.03%)
     

  • DOW

    39,131.81
    -37.71 (-0.10%)
     

  • CRUDE OIL

    83.29
    -0.09 (-0.11%)
     

  • GOLD FUTURES

    2,335.50
    -3.40 (-0.15%)
     

  • NIKKEI 225

    40,074.69
    +443.63 (+1.12%)
     

  • HANG SENG

    17,769.14
    +50.53 (+0.29%)
     

  • DAX

    18,162.12
    -128.54 (-0.70%)
     

  • CAC 40

    7,541.38
    -19.75 (-0.26%)
     
Money:

How to make sure you don’t get underpaid when it comes to state pension

Getting less than you were expecting could come as a nasty surprise but there are things you can do about it

RxSight, Inc. To Participate in the Truist Securities Medtech Conference

RxSight, Inc.
·1-min read
RxSight, Inc.
RxSight, Inc.

ALISO VIEJO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Truist Securities MedTech Conference.

RxSight’s management is scheduled to participate in a fireside chat on Tuesday, June 18, 2024, at 12:05 p.m. Pacific Time / 3:05 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+™, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com